These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1416828)

  • 1. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
    Drusano GL; Yuen GJ; Morse G; Cooley TP; Seidlin M; Lambert JS; Liebman HA; Valentine FT; Dolin R
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1280-3. PubMed ID: 1416828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Wyvill KM; Flora KP; Broder S; Johns DG
    Clin Pharmacol Ther; 1991 Sep; 50(3):278-85. PubMed ID: 1914362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Marczyk KS; Broder S; Johns DG
    Clin Pharmacol Ther; 1990 May; 47(5):647-54. PubMed ID: 2111751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
    N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.
    Balis FM; Pizzo PA; Butler KM; Hawkins ME; Brouwers P; Husson RN; Jacobsen F; Blaney SM; Gress J; Jarosinski P
    J Infect Dis; 1992 Jan; 165(1):99-104. PubMed ID: 1727902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of dideoxyinosine in pigtailed macaques (Macaca nemestrina) after intravenous and subcutaneous administration.
    Ravasco RJ; Unadkat JD; Tsai CC; Nosbisch C
    J Acquir Immune Defic Syndr (1988); 1992 Oct; 5(10):1016-8. PubMed ID: 1453316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of 2',3'-dideoxyinosine in monkeys.
    Qian MX; Finco TS; Swagler AR; Gallo JM
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1247-9. PubMed ID: 1929275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
    Bruzzese VL; Gillum JG; Israel DS; Johnson GL; Kaplowitz LG; Polk RE
    Antimicrob Agents Chemother; 1995 May; 39(5):1050-3. PubMed ID: 7625787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice.
    Manouilov KK; Xu ZS; Boudinot FD; Schinazi RF; Chu CK
    Antiviral Res; 1997 May; 34(3):91-9. PubMed ID: 9191016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.
    Knupp CA; Brater DC; Relue J; Barbhaiya RH
    J Clin Pharmacol; 1993 Oct; 33(10):912-7. PubMed ID: 8227460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
    Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.
    Kaul S; Knupp CA; Dandekar KA; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1991 Apr; 35(4):610-4. PubMed ID: 1906259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonlinear disposition of intravenous 2',3'-dideoxyinosine in rats.
    Wientjes MG; Mukherji E; Au JL
    Pharm Res; 1992 Aug; 9(8):1070-5. PubMed ID: 1409380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat.
    Ray GF; Mason WD; Badr MZ
    Drug Metab Dispos; 1990; 18(5):654-8. PubMed ID: 1981715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.